Designer Benzodiazepines

Designer benzodiazepines (DZBDs) represent a major public health issue and their prevalence has increased substantially over the last decade.1 Slight alterations…

What Did My Patient Actually Take? An Overview of Alcohol Results

According to the National Survey on Drug Use and Health conducted in 2015, 86.4% of people over the age of 18 reported drinking alcohol at some point in…

Synthetic Cannabinoids

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of prescription or illicit drugs that are…

Polysubstance Use: Fentanyl and Stimulants

The United States is in an overdose epidemic, with the CDC estimating that 106,699 individuals died of a drug-involved overdose in 2021 alone. Most deaths…

Spotlight on Potential Interactions Involving Behavioral Health & Substance Use Disorder Medications

Drug-drug and drug-food interactions (DDIs) contribute to adverse drug events (ADEs) which can range in severity from mild effects to life-threatening.…

Managing Neonatal Abstinence Syndrome: Screening and Medication Monitoring

Neonatal abstinence syndrome (NAS) affects infants who were exposed to opioids or other substances while in the womb.1 NAS has become more common in recent…

Novel Psychoactive Substances: Newly Identified Threats Detected in the Second Half of 2022

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs. There are various…